RA drug benefits 'not different'

Anti-tumour necrosis factor (TNF) drugs have the same clinical efficacy as other DMARDs, say US and Austrian researchers.

Anti-TNF drugs in combination with methotrexate are recommended as a second-line treatment for rheumatoid arthritis (RA) if patients fail to respond to DMARDs, according to NICE.

But a systematic review of 23 head-to-head trials into RA drugs showed no major or clinically important differences between the two types of drugs when used as monotherapy.

All of the trials studied included at least 100 participants and 12 weeks' follow-up. Anti-TNF drugs studied included adalimumab, etanercept and infliximab, and DMARDs were limited to methotrexate, leflunomide and sulfasalazine.

In trials comparing monotherapy with each type of drug, anti-TNF drugs resulted in better radiographic outcomes than other DMARDs.

However, when the American College of Rheumatology (ACR) response criteria was considered there was little difference in outcomes for ACR 20, 50 or 70 response rates.

Overall, combinations of treatment were found to be more effective than monotherapy.

But there is insufficient evidence to decide which combination is best, said the researchers.

They warn that, because most of the studies considered were short term, long-term safety issues may change the benefit and harm ratios of the different types of drugs.


Annals of Internal Medicine 2007 Online

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

Boris Johnson, Sajid Javid and NHS chief executive Amanda Pritchard at Downing Street press conference

GPs offered £15 per jab as government sets 31 January COVID-19 booster deadline

COVID-19 vaccine payments to GP practices will rise nearly a fifth to £15 per jab...

Houses of parliament

Evidence for mandatory NHS staff COVID-19 jabs 'not good enough', says Lords committee

Evidence to support government plans to require all NHS staff in patient-facing roles...

Dr Farah Jameel

Practices 'need substantial support' to step up Omicron response, warns BMA GP chair

General practice is already facing unsustainable pressure and will need 'substantial...

JCVI COVID-19 immunisation chair Professor Wei Shen Lim

JCVI backs immediate expansion of COVID-19 vaccination to combat Omicron variant

The COVID-19 booster campaign should expand immediately to people aged 18-39 and...

Close up of hand holding sample tube with 'Omicron' handwritten on side

Government urged to 'free up' GP practices and expand steps to control Omicron

GPs have called for immediate action such as suspension of QOF to allow practices...

(Photo: Mike Kemp/Getty Images)

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...